




Original research

Neurodegenerative disease risk among former international rugby union players

Emma R Russell,¹ Daniel F Mackay,² Donald Lyall ,² Katy Stewart,^{3,4} John A MacLean,^{3,4} James Robson,⁵ Jill P Pell,² William Stewart  ^{1,6}



SCAN ME



Neurodegenerative disease risk study: A critical appraisal

Dr Gordon Fuller
University of Sheffield



Research shows huge spike in MND risk among former international players

By Mitch Phillips



A leading expert has called for "immediate research" after a study suggested that elite rugby union players could be at increased risk of brain conditions like motor neurone disease.

Professor Willie Stewart led the research and spoke to #BBCBreakfast
bbc.co.uk/news/uk-scotland



6:30 AM · Oct 5, 2022



MailOnline

Rugby players are up to 15 TIMES more likely to get deadly brain diseases like dementia, warns landmark study into 'sport's silent scandal'



Rugby urged to cut matches as study finds players' risk of MND is 15 times higher

Rugby union

- Study also finds increased risks of dementia and Parkinson's
- Consultant says contact training 'should be a thing of the past'

Retired Pro Rugby Players Face More Than Double the Odds for Brain Illnesses



Rugby authorities urged to cut out contact training to reduce the risk of Motor Neurone Disease

Study found that ex-rugby players had more than twice the risk of a neuro-degenerative disease, and a 15-times higher risk of a motor neurone disease diagnosis.

NewScientist


International rugby union players face higher risk of dementia

Men who played rugby union for Scotland are much more likely to develop dementia, Parkinson's disease and motor neurone disease than the rest of the population



Study finds higher neurodegenerative disease risk for international rugby players; Dementia, motor neurone disease more likely





'Fantasy' Study:




'Best possible' Study: Internally valid retrospective cohort

All rugby players:

- Accurately identify all rugby players
- Accurately measure head impacts
- Accurately measure all confounders
- Accurately measure outcomes

Controls:

- Accurately identify representative controls
- Accurately measure head impacts
- Accurately measure all confounders
- Accurately measure outcomes



- Control group is identical to rugby group, except for head impacts
- Causal graphs
- Matching, restriction
- Regression, propensity scores, etc



Carefully and systematically examining research to judge its trustworthiness, its value and relevance

Critical Appraisal

1

What was done?

2

What were the results?

3

Can we believe the results?

4

Do the results apply to us?

5

What does this study add to what is known already?

6


What's the bottom line?

1

What was done?

Retrospective Cohort Study

EXPOSED



Male Scottish internationals aged 30+ @2020.



Median 32 years follow up to Dec 2020


CONTROLS




- 3:1 population controls
- Matched on age, sex, year of birth, socioeconomic status



- Mortality:
 - Death certificates
- Neurodegenerative disease (ICD 9-10):
 - Hospitalisations [Scottish Morbidity Record]
 - Dispensed prescriptions [Prescribing Information System]
 - Death certificates



Neurodegenerative disease



Neurodegenerative disease	HR/OR (95% CI)
Dementia (NOS)	2.17 (1.26 to 3.72)
Parkinson’s disease	3.04 (1.51 to 6.10)
MND/ALS‡	15.17 (2.10 to 178.96)



‘Systematic errors that result in an incorrect estimate of the association between exposure and the health outcome’



SELECTION BIAS



INFORMATION BIAS



CONFOUNDING



- Which biases DISTORSIONI?
- How likely?
- Direction?
- Magnitude?



- '37% of our potential cohort of former international rugby players could not be matched CORRISPONDONO to their health records'
- Migration/loss to follow up (informative right censoring)?

Utility of Scottish morbidity and mortality data for epidemiological studies of motor neuron disease

A M Chancellor¹, R J Swingler, H Fraser, J A Clarke, C P Warlow

Conclusions: Coded hospital discharge data are an inaccurate record of a diagnosis of MND and cannot, in their present form, be used as a reliable measure of disease incidence in Scotland.



- Inaccurate outcomes - Death certificates, Scottish Morbidity Record, ICD 9/10 codes

- Likelihood – Probable
- Magnitude – Uncertain, but possibly small
- Direction – Uncertain, likely to underestimate risk?

What Are Internal and External Validity?


Do the results apply to us?

Relates to how well a study is conducted

Relates to how applicable the findings are in the real world

(If true) are these results relevant to me?

- Scotland Vs other countries?
- Historical Vs current rugby?
- Elite Vs community rugby?
- Males Vs females?
- Adult Vs youth rugby?
- Rugby Vs other collision sports?



- Many previous studies
- Similar study designs
- Similar results in elite athletes
- No association in amateurs



Bradford-Hill Criteria: Viewpoints to determine if causation CAUSALITA' can be deduced

6 What's the bottom line?

THE BOTTOM LINE

What we want to know:

- Do head impacts in rugby cause neurodegenerative disease?
- If so, what is the absolute increase in risk due to head impacts?

What we can say from this study:

- Do head impacts in rugby cause neurodegenerative disease? **We don't know**
- If so, what is the absolute increase in risk due to head impacts? **We don't know**

However:

- (Some) NDD is (probably?) possibly more common in Rugby internationals compared to general population controls
- Cannot say if this is due to head impacts/concussions, or another reason e.g. alcohol



Vs








Table 1 Cohort demographic information

	Former international rugby players (n=412)	Matched population comparison group (n=1236)
	Number (%)	
SIMD quintile		
1	11 (2.7)	33 (2.7)
2	41 (10.0)	123 (10.0)
3	66 (16.0)	198 (16.0)
4	127 (30.8)	381 (30.8)
5	167 (40.5)	501 (40.5)
Player position		
Forward	222 (53.9)	N/A
Front row	96 (23.3)	N/A
Lock	40 (9.7)	N/A
Back row	86 (20.9)	N/A
Backs	190 (46.1)	N/A
Half backs	58 (14.1)	N/A
Three quarters	111 (26.9)	N/A
Fullback	21 (5.1)	N/A
Year of birth		
1900–1919	47 (11.5)	141 (11.5)
1920–1939	91 (22.1)	273 (22.1)
1940–1959	89 (21.6)	267 (21.6)
1960–1979	109 (26.4)	327 (26.4)
1980–1990	76 (18.5)	228 (18.5)
N/A, not applicable; SIMD, Scottish Index of Multiple Deprivation.		



What were the results?

Mortality

Primary cause of death	Former international rugby players (n=412)	Matched population comparison group (n=1236)	HR (95% CI)
Any cause†	121 (29.4%)	381 (30.8%)	0.86 (0.68 to 1.08)
Cardiovascular disease	54 (13.1%)	155 (12.5%)	0.89 (0.63 to 1.28)
Cancer	30 (7.3%)	108 (8.7%)	0.77 (0.50 to 1.19)
Neurodegenerative disease	11 (2.7%)	18 (1.5%)	2.43 (0.92 to 6.42)
Respiratory disease	11 (2.7%)	43 (3.5%)	0.62 (0.28 to 1.39)

Neurodegenerative disease

	Former international rugby players (n=412)	Matched population comparison group (n=1236)	HR (95% CI)
All NDD	47 (11.4%)	67 (5.4%)	2.67 (1.67 to 4.27)
Deaths	32 (7.8%)	39 (3.2%)	2.60 (1.44 to 4.70)
Hospitalisation	21 (5.1%)	37 (3.0%)	2.29 (1.19 to 4.41)
Prescribing NDD	24 (5.8%)	28 (2.3%)	4.59 (2.14 to 9.82)
Neurodegenerative disease			HR/OR (95% CI)
Dementia (NOS)			2.17 (1.26 to 3.72)
Parkinson's disease			3.04 (1.51 to 6.10)
MND/ALS‡			15.17 (2.10 to 178.96)

Supplementary Table 1: ICD-9 and ICD-10 codes for outcomes assessed.

	ICD-9	ICD-10
Neurodegenerative disease	290.0 to .4; 294.1 & .2; 331.0 to .2 & .6 to .9; 332; 335.2	F01 to F03; G12.2; G20; G21; G23.1 to .3, .8 & .9; G30; G31
Dementia, not otherwise specified	290.0 to .4; 294.1 & .2; 331.0 to .2 & .6 to .9;	F01 to F03; G23.1 to .3; G30; G31
Motor neuron disease/ Amyotrophic lateral sclerosis	335.2	G12.2
Parkinson's disease	332	G20; G21; G23.8 & .9
Cardiovascular disease	390 to 459	I00 to I99
Respiratory disease	460 to 519	J00 to J99
Cancer	140 to 239	C00 to D49

BNF section	Drugs
4.9.1	Apomorphine hydrochloride Apomorphine hydrochloride hemihydrate Carbidopa Co-beneldopa (Benserazide/levodopa) Co-careldopa (Carbidopa/levodopa) Entacapone Levodopa Levodopa/carbidopa/entacapone Opicapone Rasagiline mesylate Safinamide Selegiline hydrochloride Tolcapone
4.9.2	Orphenadrine hydrochloride Trihexyphenidyl hydrochloride
4.9.3	Riluzole
4.11	Donepezil hydrochloride Galantamine Idebenone Memantine hydrochloride Rivastigmine

Caveats

A B C D